Back to the atlasDownload source notes

October 23, 2026 — combined scheduled focused research update

Home · Latest · Milestones

This completes the unfinished October 20 research collection and adds a bounded October 21–23 follow-up. It is not a claim that the October 20 run previously completed or published. All 32 active condition topics are covered below; the retained Sleep hub preserves history without a duplicate assignment. Prior full successful-check dates remain unchanged. Source, publication, event, verification and completion-estimate dates remain separate. Bulk registry downloads are not exhaustive worldwide appraisal.

Findings

Coverage by topic

Whole-body MRI

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: whole body mri; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Read current notes and state; retrieved HERCULES and both discovery records. The new matches concern treatment or imaging measurements, not general-population screening. The October 1 review was deduplicated. The October 14 SABI schedule was opened, but delivered talks, slides and the worldwide outcomes/guidance inventory remain unappraised. Retain the full successful-check timestamp.

October 23 bounded delta: No dedicated October 21–23 MRI primary-source search was completed in this bounded delta. The last collected registry coverage is October 20; this is a gap, not a no-news conclusion.

Informal sources and unresolved claims: Indexed original MRI discussions supplied no distinct new development signal. Commercial-scan experiences and older claims were not converted into outcome evidence. SABI talks and complete podcast audio remain unreviewed. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Galleri and organ-specific cancer screening

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: galleri; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all 158 discovery records across two pages. Checked current GRAIL news and the October 5 conference announcement; October 25/26 presentations remain scheduled. Natera, SOARA, SAFE-MRI and prior EDCC findings were deduplicated. ANIHTA was appraised as a new observational protocol. The complete organ-specific inventory, ESMO tables and original ABUS paper remain gaps; JACR returned 403. Retain the full successful-check timestamp.

October 23 bounded delta: Read the current GRAIL clinical-evidence index. No newly released October 21–23 outcome table was selected. October 25/26 ESMO presentations remain future as of October 23. October 15 psychological/behavioral posters were identified but not fully appraised in this bounded delta; organ-specific screening and worldwide entrants remain incomplete.

Informal sources and unresolved claims: Revisited approval-timing speculation and sponsor news. No new FDA approval document or official action day was verified. An October 18 panel recap repeats the September 23 vote. Generic scan anecdotes and stock-price hopes were excluded. Complete investor audio/transcript coverage remains incomplete. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Oct20 named therapies + human trial results/holds/discontinuations/new entrants; complete specified CTgov discovery; Oct23 site:investor.lilly.com October 2026 October 22 eloralintide retatrutide AMPLIFY

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 930 records across 10 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; New-record leads LY4167586 NCT07881887 and NKS3 NCT07882654 were discovered October 20 but mechanism/development context is not fully appraised. Do not call NKS3 an incretin; its record describes modified-linoleic-acid fat-taste receptor activity. No results incorporated.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Re-read October 9 Eloralintide trial thread; appetite/skin/sleep accounts unchanged. SOLIS-1 original remained inaccessible. Near-30%/future-combination/titration forecasts remain unconfirmed; AMPLIFY registration does not confirm efficacy rumors. October 21 Reddit AMPLIFY repost links the same official protocols and is not independent confirmation.

Sources checked:

Muscle building and preservation

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for muscle.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (27 records). October 23 extended discovery through October 21–23 (2 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved. COURAGE full in-press publication and BELIEVE withdrawal-phase detailed safety remain unrecovered.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. Enobosarm Cantor Phase 3 direction remains unconfirmed; original recording and actual Phase 3 initiation were not verified. COURAGE reposts repeat the October 1 sponsor report.

Sources checked:

Longevity and healthspan trials

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: October 20 named-program checks, ClinicalTrials.gov specified discovery query and selected primary/informal searches; no dedicated October 21–23 delta.

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 56 records across 1 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; NCT07880925 trigonelline study was discovered October 19: planned four-week NAD biomarker study, not proven healthspan benefit. Lead retained for later appraisal. TAME direct page returned 404 again; indexed fundraising text is not evidence of current funding or trial start.; No dedicated October 21–23 longevity delta completed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Vitaei PEARL 24-month claim unchanged; its offered DOI remains unrelated, so prior unconfirmed/contradicted-citation status remains. TAME start/funding not verified.

Sources checked:

Localized fat removal and cellulite

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28CBL-514+OR+RZL-012+OR+tesamorelin+OR+cellulite+OR+submental+fat+OR+localized+adipose%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22cellulite%22+OR+%22localized+fat%22+OR+%22tesamorelin%22+OR+%22submental+fat%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; Caliway October21–23 CBL514 Phase3 trial news

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (110 records) and all 15 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 6 of 6 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; SUPREME-01 NCT07140939 updatedOctober 19 but retains 320 target, recruiting status, actual September 1 start, July 2027 primary / September 2027 final estimates and the same six recruiting cities among 13 listed locations. No enrollment count/completion or new Phase 3 efficacy. CBL-0206 Stage 1 NCT07608770 now records actual June 1, 2026 start; sponsor had already announced enrollment July 3. Stage 2 NCT07608757 remains not yet recruiting withFebruary 2027 / February 2028 / June 2028 estimates. Metadata changes are not a new clinical result.; Newly first-posted NCT07880301 is a 37-person deoxycholate/cellulite study completed 2021, with no posted results; retrospective registration is not a new 2026 treatment trial or proof of efficacy. Subcutaneous fat, visceral fat, liver fat, cellulite dimpling and symptom change remain separate. No new SUPREME-02 enrollment milestone, RZL-012 China filing or broader tesamorelin indication verified.; October 23 delta: Caliway original news index still leads with October 2 EASD and September 23 first-dose announcements. No additional result selected from this bounded source check. No fresh complete registry refresh.

Informal sources and unresolved claims: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Broad cardiovascular prevention, lipids and screening

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: October 20 named-program checks, ClinicalTrials.gov specified discovery query and selected primary/informal searches; no dedicated October 21–23 delta.

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 608 records across 7 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; No dedicated October 21–23 cardiovascular delta completed; the October 20 results appraisal is retained without advancing timestamps.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. October 9 Dr Hillary Lin podcast show description/time markers (00:45 HORIZON; 18:37 LDL pill; 20:44 aging clocks) recycled known prior events; full audio not appraised and no new result inferred.

Sources checked:

Alzheimer's screening and therapies

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: alzheimers; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all 43 discovery records. Most new matches concern diagnostics, devices or observational work. API-2 randomization and PLASMAR were deduplicated. An October 19 CELIA media recap traces to May/July data. The original Longo transcript was read for a planning statement. Complete registry, label, CTAD, PET/tau and acquired-cognition safety inventories remain incomplete. Retain the full successful-check timestamp.

October 23 bounded delta: Appraised the October 22 Vanderbilt KeTADiD announcement through mental-health coverage and cross-linked it here. No independent complete Alzheimer regulator, registry or human-study delta sweep was completed.

Informal sources and unresolved claims: Recorded the new original Longo statement with sponsorship, timestamps, funding uncertainty and no verified launch. The saved Davidson/obicetrapib prevention hypothesis remains clinically unconfirmed; SPINOZA recruitment was already reported. Other cognition podcasts were explored selectively, with complete audio/transcript coverage still incomplete. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: psychedelics; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all 13 discovery records. The driving protocol, IBO-CARE and FDA ibogaine request were deduplicated. PSiGAD2 stopping was appraised from indexed primary ISRCTN content; direct access required cookies/JavaScript. ISRCTN XML, CTIS, detailed APPROACH harms and the complete global inventory remain incomplete. Retain the full successful-check timestamp.

October 23 bounded delta: Verified ICER’s October 21 announcement, actual assessment timeline and draft scope. A Parkinson biomarker research-letter lead had an inaccessible full article and was not treated as new clinical benefit. This is not complete worldwide trial or informal-source coverage.

Informal sources and unresolved claims: The original October 19 investor thread discusses a go-slow-to-go-fast remark without a recovered original recording establishing NDA timing. The existing 44–81-day inference remains unconfirmed. Reviewed Compass news supplied no final NDA filing confirmation. Reported Resilient MDMA resubmission still lacks independently verified FDA acceptance/action timing. No repeat alerts for unchanged claims. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: ssri antidepressants; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all 639 broad discovery records across seven pages after paced retries. Many matches were incidental diagnoses. Appraised the new open-label PTSD/suicidal-ideation deep-TMS protocol. MHRA, WELTRUZA, BALANSYA and prior negative MOONLIGHT/fasedienol findings were deduplicated. Complete drug-label safety, bipolar/OCD/addiction long-term studies and full VNS results remain incomplete. Retain the full successful-check timestamp.

October 23 bounded delta: Appraised the original Vanderbilt October 22 KeTADiD announcement, preserving its planned start, missing registry/phase/sample details and safety focus. Other psychiatric indications, new entrants and informal sources were not comprehensively rechecked.

Informal sources and unresolved claims: Targeted original Reddit and podcast searches did not establish a distinct new attributable development rumor. AJP VNS discussion remains an interpretation lead, not appraised new efficacy or scheduled approval. Patient experiences and repeated MHRA links were not used to estimate trial safety; complete audio coverage remains incomplete. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Bone health, joint preservation and cartilage repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for joint_preservation.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (122 records). October 23 extended discovery through October 21–23 (23 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved. TG-C ACTiVION-I October forecast and full AGILI-C reoperation/harms tables remain unverified; no result inferred from elapsed dates.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete.

Sources checked:

Liver health and noninvasive assessment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Oct20 MASH/liver human trial discovery and named programs; Oct23 site:ir.madrigalpharma.com October 2026 October 22 resmetirom

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 150 records across 2 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; DR10624 liver-fat finding is owned by cardiovascular and cross-linked here; do not duplicate the event. New resmetirom protocols are recovered baseline context, not an October 23 result.; October 23 bounded search of Madrigal releases/pipeline recovered existing plans, not a newly appraised clinical readout. Complete MASH conference/negative-data review remains open.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Revisited September 18 Wegovy/CHMP omission thread and current EMA overview. Omission does not establish rejection or resolve the MASH procedure; no status change verified.

Sources checked:

Cancer treatment, vaccines and recurrence prevention

Coverage: focused_incomplete. 10 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: cancer vaccines; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all 79 discovery records. Appraised FDA approvals/labels, negative BNT113 topline results, BEX101 and RO7821657 protocols, the AZA-AEGEAN hold and older studies with newly posted tables. Root-supplied registry leads were included. CDX-1401 NCT03206047 stopped in 2020 for supply/product reasons and had zero vaccine-arm participants; it was excluded as vaccine failure. ESMO October 23–27 and INTerpath-001 October 24 remain future. The worldwide oncology, regulator, label and new-protocol inventory remains incomplete. Retain the full successful-check timestamp.

October 23 bounded delta: Verified the original Merck October 22 detailed INTerpath-001 release, including primary ITT estimates, harms and immature overall survival. The October 24 talk has not yet occurred. Checked ESMO sponsor schedules; unverified future talks, unpublished full tables and secondary NATALEE claims were not converted into results. This is a bounded delta, not exhaustive worldwide oncology monitoring.

Informal sources and unresolved claims: Original October 19 REGAL discussion continues to speculate about event 80, survival and an anniversary post without verified arm outcomes. The saved imminent-trigger claim remains unconfirmed rather than disproved. The sponsor index dynamically hid items; no official event-80 release was independently retrieved. CytoDyn/CLOVER investor ctDNA remarks remain an original-webcast access gap, not established efficacy. Full investor audio and ESMO abstract coverage remain incomplete. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Autoimmune disease and immune reset

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for autoimmune.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (38 records). October 23 extended discovery through October 21–23 (3 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved. The original October 21 sponsor text was readable through indexed primary content, while direct requests returned 403. Full poster and BMS Breakfree-2 conference data remain gaps; no restart inferred.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. Saved Mount Sinai IBD CAR-T planning remains unconfirmed. A conference cohort does not resolve unrelated rap-cel/zola-cel safety holds.

Sources checked:

Non-opioid pain treatments

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for pain.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (60 records). October 23 extended discovery through October 21–23 (11 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. Original patient comments about Journavx and ketamine-like compounds were not treated as controlled outcomes or new development decisions.

Sources checked:

Kidney preservation and earlier detection

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Oct20 renal trials named/discovery + ASN official announcements; Oct23 pegcetacoplan October 22 ASN actual results; schedule recovered, tables not retrieved

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 424 records across 5 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. October 16 u/TheFightingSloths ADPKD post repeats recruiting news and speculates about 2029 availability/fast track; anonymous friend/doctor accounts do not establish an FDA designation, approval timetable or superiority to tolvaptan. Similar forecasts predated this post, so no independent confirmation/status upgrade or repeat alert.

Sources checked:

Hearing and vision preservation/restoration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: hearing vision; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all 15 saved named registries and all 574 discovery records across six pages after paced retries. Appraised the LUCIA release, SEC slides and separate decision to end wet-AMD follow-up early. AC102 still reflects a January 16 record with elapsed completion estimates and no posted results. The October 21 4DMT event remains future. Complete BRUNELLO, MCO-010 and BEST1 tables, inherited/acquired sensory inventories and regulatory labels remain gaps. Retain the full successful-check timestamp.

October 23 bounded delta: Read the actual October 21 4DMT investor-day deck. PRISM pages use a May 18 cutoff and SPECTRA repeats September two-year data; these were not presented as fresh efficacy. The deck verifies future 4FRONT forecasts. No complete October 21–23 acquired/inherited sensory delta sweep was performed.

Informal sources and unresolved claims: An October 14 AC102 thread recycles 2025 gerbil research; original comments distinguish that from human sudden-hearing-loss development. It does not confirm the saved purported-email claim of conditional 2027 Phase 3/tinnitus plans. No actual human tinnitus result was established. Other patient claims and complete AAO investigator audio remain unappraised. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Hair loss, restoration and graying

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28alopecia+OR+hair+graying+OR+hair+greying+OR+hair+repigmentation%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22alopecia%22+OR+%22hair+greying%22+OR+%22hair+graying%22+OR+%22hair+repigmentation%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; site:ir.veradermics.com October 2026 21 22 23 VDPHL01; site:fda.gov VDPHL01 minoxidil Veradermics approval; site:reddit.com/r/tressless VDPHL01 October2026 results304

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (108 records) and all 20 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 156 of 156 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; PP405 October 14 first-dose milestone, adolescent baricitinib approval and adult long-term BRAVE-AA findings are already saved and were not re-alerted. No new formal BQ-002 human study, GT20029 pivotal start or clascoterone hair-indication approval verified. VDPHL01 Study 304 registry target480 remains stale versus sponsor536; primary registry has no posted results.; Female Study306 registry lists Phase3, planned552 and June2027 primary estimate; October19 sponsor calls it Phase2/3 with556 enrolled and forecasts first-half2027 topline. Preserve differing current sources; do not conflate women's investigational findings with approved use.; October 23 delta: Veradermics original news index still leads with October 19 Study304 results; no later efficacy, safety or approval announcement selected. October 19 SEC-filed deck corroborates536total and arm populations178/177/181. Sponsor-only result remains investigational for pattern hair loss; no active minoxidil comparator. Indexed FDA search did not identify VDPHL01 approval, which is not a complete database clearance audit.

Informal sources and unresolved claims: Revisited the original BQ-002 2027 Phase1 claim and sponsor pipeline: candidate existence corroborated, candidate-specific human registration/start and 2027 timing still unverified. Revisited July26 clascoterone launch inference and Cosmo July23 Q1/Q2 2027 filing forecasts; no new approval/launch confirmation. October4 self-experiment-based PP405 pessimism and PP405 first-dose reposts supply no new controlled efficacy or independent corroboration. Full audio remains unreviewed. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete. October19/20 VDPHL01 threads and October21 comments repeat sponsor results, add unsupported late2027/2028 launch predictions and conflicting safety/superiority claims. They do not establish an active-comparator trial, elimination of cardiac risk, or a verified launch date. Gray-market lookalike-product anecdotes were excluded from trial safety evidence.

Sources checked:

Skin aging, laxity and regeneration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28skin+aging+OR+skin+laxity+OR+skin+rejuvenation+OR+KB304+OR+microcoring%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22skin+rejuvenation%22+OR+%22skin+laxity%22+OR+%22photoaging%22+OR+%22polynucleotide%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; skin rejuvenation clinical trial October21 October22 October23 2026

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (90 records) and all 11 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 60 of 60 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; October 23 delta: bounded dated discovery returned older studies, reviews and cosmetic/mechanistic leads rather than a selected new October21–23 human outcome. Full journals, original conference abstracts, regulatory and device census not repeated.

Informal sources and unresolved claims: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Scar prevention, treatment and stretch marks

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28scar+OR+keloid+OR+stretch+mark+OR+verteporfin+OR+siSPARC%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22keloid%22+OR+%22hypertrophic+scar%22+OR+%22stretch+marks%22+OR+%22scar+prevention%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; Syntara scars October21 October22 2026; site:reddit.com verteporfin October2026 scar trial

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (257 records) and all 13 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 33 of 33 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; SNT-9465 October 1 expansion / Q1 2027 topline forecast already saved; Syntara news index contains no newer scar result selected. SCARFREE and Geneva verteporfin status/results remain stale or unverified. NCT07878390 SYLKE split-wound abdominoplasty dressing registration is already present; no result. Newly registered NCT07880860 recruits 40 infants for placebo-controlled botulinum toxin cleft-lip scar prevention, actual February 19 start, February 2027 primary / February 2032 completion estimates; no efficacy and no inference to erasing old adult scars or stretch marks.; October 23 delta: Syntara original news index and targeted scar/verteporfin discovery did not produce a selected new scar outcome or revised SNT9465 milestone. Current Q12027 forecast remains separate from results. No complete fresh registry or informal-audio census.

Informal sources and unresolved claims: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Facial volume restoration and contour

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28dermal+filler+OR+facial+volume+OR+facial+fat+graft+OR+nasolabial%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22facial+volume%22+OR+%22dermal+filler%22+OR+%22facial+fat+graft%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; Belotero Volume launch October2026 Merz

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (105 records) and all 7 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 14 of 14 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; Current Merz U.S.news index still points to September 14 Belotero announcement with October 14Volume and December 1 Intense anticipated commercial dates. No independent actual U.S.launch/inventory verification; October 14remains elapsed forecast. Latest volume/fat-grafting literature includes reviews/technical descriptions, not a selected new controlled durable-benefit result. NCT07877870 completed thread-lift comparison is first posted October 16 with no results; registration is not efficacy.; October 23 delta: Merz original news index retains September14 announcement. A recovered October interview still speaks prospectively about a broad mid-October launch and does not verify actual provider inventory; it also misdates original FDA approvals as September14. The original FDA PMA dates remain authoritative, and October14 actual availability remains unverified.

Informal sources and unresolved claims: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Pigmentation and uneven skin tone

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28melasma+OR+vitiligo+OR+hyperpigmentation+OR+solar+lentigines%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22melasma%22+OR+%22hyperpigmentation%22+OR+%22solar+lentigines%22+OR+%22vitiligo%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; vitiligo melasma trial October21 October22 October23 2026

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (59 records) and all 11 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 130 of 130 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; Reviewed new NCT07881328 melasma 128-person prognostic study of dermoscopic vascular score under uniform oral tranexamic acid: not yet recruiting, November 2026/June2027estimates, no results or randomized therapy comparison. Vitiligo Phase 3 named records and toner-adjunct result deduplicated. October 13 CXCL10 mechanism paper is biomarker correlation, not new comparative efficacy; full text returned HTTP 403. October 16 melasma HA/glutathione+laser+TXA observational paper could not be retrieved; clinical significance, contribution of each component and detailed harms remain unappraised.; NCT07881367 vitamin K2 dark-eye-circle study was first posted October 19 but actually completed July 2024, enrolled34, with no posted results. A result-sounding registry title does not supply efficacy; not promoted as new clinical benefit.; October 23 delta: bounded discovery found routine newly registered vitaminC/niacinamide comparison and an older October16 HA/GSH/laser/TXA source. No new controlled October21–23 result appraised. Registry mirrors are leads only; no baseline expansion or new efficacy selection.

Informal sources and unresolved claims: October 16 r/Melasmaskincare imaging-paper discussion was checked as a lead; it reports 15 patients and predictive markers rather than treatment confirmation. Multi-treatment personal improvement, referral-code posts and unverified argireline pigment claims were not promoted as formal outcomes. Original podcast/talk coverage incomplete. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Acne and rosacea

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28acne+OR+rosacea+OR+denifanstat+OR+B244%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22acne%22+OR+%22rosacea%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; rosacea denifanstat acne October21 October22 October23 2026

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (62 records) and all 13 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 135 of 135 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; AURORA denifanstat NCT07863193 remains recruiting 800; B244 rosacea NCT07866105 remains not yet recruiting 176. Saved denifanstat extension and October 9 site-activation source deduplicated. New NCT07883538 clascoterone-versus-adapalene 130-person recruiting comparison reviewed, but no outcome selected. Newly first-posted completed IDP trials do not automatically supply new trial data; existing prior results separated.; October 23 delta: Sagimet original news index and dated acne/rosacea discovery yielded no additional selected clinical result beyond preserved October14/19 evidence. Full source/registry and audio coverage not repeated; no whole-topic no-news conclusion.

Informal sources and unresolved claims: October 7 Ontario rosacea recruiting post refers to a trial link and Phase 2 pustule study without establishing new efficacy; no assumption all rosacea is one pathway. October 10 self-described South Florida research coordinator advertises a small randomized hypochlorous-acid routine/well-being study with IRB 2026-125 but institutional identity/protocol/registry not independently matched; not selected as verified trial progress. Original audio coverage incomplete. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Dental alignment, regeneration and repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: https://clinicaltrials.gov/api/v2/studies?query.term=%28orthodontic+OR+aligner+OR+tooth+regeneration+OR+enamel+OR+periodontal+regeneration%29+AND+AREA%5BLastUpdatePostDate%5DRANGE%5B2026-09-05%2C2026-10-20%5D&pageSize=100&format=json&sort=LastUpdatePostDate%3Adesc&countTotal=true; https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TITLE_ABS%3A%28%22orthodontic%22+OR+%22aligner%22+OR+%22tooth+regeneration%22+OR+%22enamel+remineralization%22+OR+%22periodontal+regeneration%22%29+AND+FIRST_PDATE%3A%5B2026-09-05+TO+2026-10-20%5D+AND+SRC%3AMED&format=json&resultType=core&pageSize=1000; dental orthodontic regeneration clinical trial October22 2026; site:reddit.com dental trial October2026 tooth regeneration

Coverage and gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (162 records) and all 12 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 242 of 242 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; Toregem news index now includes October 20/October 6 exhibition items but no verified new TRG035 dosing or efficacy beyond August 17 trial-notification review. Formal new Boston University NCT07881146 attachment cohort plans 18, not yet recruiting, December 2026 / December 2027 estimates, no results; units for translation/vertical displacement and 18-month retention window versus 12-month completion need clarification. New late-registered completed gingival/orthodontic cohorts have no posted results and do not establish new efficacy.; Original NCT07176871 cross-check now retrieved: completed July 1, 2025, retrospectively registered September 16, 2025, 52 actually enrolled versus publication 46 randomized/44 completing. Difference retained rather than silently harmonized. NCT07883005 SALI-10 supportive-care DIAMOND Phase3 planned288, not yet recruiting, November1,2026start/November1,2031completion estimates; no outcomes or tooth regeneration. Lead reviewed, not selected as a new efficacy item.; October 23 delta: Toregem index retains October20 exhibition news, without a selected clinical dosing/efficacy announcement. New topical/nanohydrogel registry-mirror leads have no appraised outcomes; enamel reports in extracted teeth remain in vitro and were excluded from human clinical efficacy. No full registry/literature census repeated.

Informal sources and unresolved claims: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Sources checked:

Allergy and airway disease

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for allergy_airway.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (155 records). October 23 extended discovery through October 21–23 (25 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete.

Sources checked:

Infectious-disease prevention and treatment

Coverage: focused_incomplete. 4 newly recorded entries.

Searches: September 5–October 20 paginated named-program and new-entrant discovery; October 21–23 registry extension for infectious_disease.; Primary sponsor, regulator, investigator and human-research follow-up; original Reddit/podcast and unresolved-claim searches.

Coverage and gaps: October 20 registry review retrieved all named records and every page of September 5–October 20 discovery (376 records). October 23 extended discovery through October 21–23 (47 records) and rechecked selected priority programs. All retrieval errors were resolved. Retrieval is not exhaustive appraisal: worldwide registries, all primary publications/harms, conference posters and original recordings remain incomplete. Earlier full successful-check dates are preserved.

Informal sources and unresolved claims: Targeted original Reddit, interviews, podcasts and saved unresolved-claim searches were checked selectively on October 20 and October 23. Reposts, product promotion and anecdotes do not establish a formal efficacy/safety result; comprehensive original audio/transcript coverage remains incomplete. The October 19 Communicable episode discusses published antibiotic trials; its linked papers/complete audio were not fully appraised. No additional trial result was inferred from commentary. The adibelivir CTIS administrative-modification claim remains unverified and non-material.

Sources checked:

Genetic screening and risk prediction

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Primary trials, results, safety, approvals and new programs since September 5, with emphasis on October 16–20, 2026: genetic screening; Original Reddit, podcast/talk transcript and unresolved informal-signal searches for this topic.

Coverage and gaps: Retrieved all saved named registries and all six discovery records after paced retries. Appraised the MiGHT randomized paper and final October 19 JAMA CD36 study, preserving final versus preprint denominators. Yale, ELISABETH and prior newborn findings were deduplicated. Prospective PGT-P offspring outcomes, commercial guidance, Generation/WISDOM and cross-ancestry PRS inventories were not comprehensively refreshed. Retain the full successful-check timestamp.

October 23 bounded delta: October 22 genomics leads were encountered but their original studies/program documents were not appraised. No new complete genetics primary-source sweep was performed; retain October 20 coverage and all previous gaps.

Informal sources and unresolved claims: The Nucleus/Vitruvian 14-point claim remains model-based and unconfirmed as selected-offspring benefit. Targeted discovery did not establish prospective child outcomes or another distinct development rumor. Earlier source-chain caveats remain; complete original social/audio coverage was not performed. October 23 delta did not complete a new broad Reddit/podcast/talk review; unresolved earlier claims retain their prior status. No anonymous prediction was promoted into established evidence.

Sources checked:

Insomnia

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: Oct20 insomnia drugs/CBT-I/digital human discovery and daridorexant harms full paper; Oct23 Idorsia pediatric ECNP October 23 actual data; presentation tables not retrieved

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 294 records across 3 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.; October 23 bounded follow-up did not retrieve actual tables for the scheduled daridorexant pediatric ECNP presentation. The elapsed schedule is not proof of delivery/results. Full baseline and comparative sleep-architecture coverage remain incomplete.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Sampled DORA/architecture patient discussion; no verified PSG result or new general safety conclusion adopted. Personal responses are not causal trial evidence.

Sources checked:

Obstructive sleep apnea

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Oct20 AD109 CHEST 2026 and named OSA drugs/devices; Oct23 site:apnimed.com CHEST 2026 October 22 AD109 menopause results 2026; Oct23 exact menopause abstract title; original abstract not retrieved

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 145 records across 2 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; October 23 follow-up searched for actual AD109 CHEST data. The October 12 sponsor schedule was recovered, but the original menopause abstract and other late-breaker tables were not retrieved. A named investigator interview published October 22 describes hypothesis-generating post hoc subgroup observations; do not convert its secondary numerical summary into a fully verified primary dataset or infer completion of all five abstracts.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence.

Sources checked:

Narcolepsy & excessive sleepiness

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Oct20 orexin/NT1/NT2/IH named programs + human discovery; Oct23 site:takeda.com October 2026 oveporexton DEA ORZEYFUL launch October 23

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 27 records across 1 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; An October 23 TGA listing describes a lapsed priority-review determination (review April 2; lapse October 2). This is not proof of Australian approval, rejection, trial hold or a new October 23 clinical event. No claim promoted.; October 23 was a bounded source follow-up only; broad registry discovery remains the October 20 snapshot. No full successful check is claimed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Re-read TAK-360/Kyra participant thread; prior wakefulness/night-awakening anecdote unchanged, dose/assignment/causality unverified. No repeat alert.

Sources checked:

Circadian rhythm disorders

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: October 20 named-program checks, ClinicalTrials.gov specified discovery query and selected primary/informal searches; no dedicated October 21–23 delta.

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 343 records across 4 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; No new clinical finding promoted. SmartEnLite NCT07883291 was discovered October 20 (lighting/crossover in nursing-home dementia; behavioral primary outcomes and wearable rest/activity), but complete appraisal remains pending. Do not represent wearable metrics as PSG architecture or dementia disease modification. No dedicated October 21–23 primary-source delta completed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. DSPD/Non-24 personal-burden discussions sampled; no new clinical or program claim promoted.

Sources checked:

Restless legs syndrome

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: October 20 named-program checks, ClinicalTrials.gov specified discovery query and selected primary/informal searches; no dedicated October 21–23 delta.

Coverage and gaps: Focused incomplete coverage. All pages of the specified ClinicalTrials.gov discovery query and saved named records were retrieved on 2026-10-20; retrieval is not exhaustive appraisal of every record or worldwide evidence. Do not advance full successful-check timestamps. Original source dates remain unchanged. Independent non-US registries, complete conference tables/audio, and a comprehensive harms/discontinuation census remain incomplete.; ClinicalTrials.gov discovery: 13 records across 1 retrieved pages; final retrieval errors: []. Named records also retrieved successfully.; Sleep incomplete baselines used 90-day context through October 20; other topics used the last full successful check minus seven days. Earlier October 16 focused checks did not reset that window.; No new finding promoted. NCT07397247 TOMAC/dopaminergic augmentation lead and full current device/medicine harms evidence still need appraisal. Existing 2026 algorithm was not treated as new solely because of its later issue date. No dedicated October 21–23 primary-source delta completed.

Informal sources and unresolved claims: Original informal sources were sampled on October 20; not a comprehensive podcast, social-media, or anonymous-source search. Reposts were not treated as independent confirmation. No resolved claim was inferred from source silence. Sampled Nidra response/discomfort and insurer-approval/denial accounts; these are individual experiences, not new formal results or nationwide coverage evidence.

Sources checked:

Homepage and publication

The October 3 EloraTZP feature was reviewed and retained: matching-arm efficacy and harms remain useful, while the newly registered AMPLIFY studies provide no Phase 3 results. New melanoma findings appear in the dated feed and topic summary rather than being forced into a weight-loss chart. The feature is due for reconsideration at the next substantive release, with evidence quality and variety prioritized. Historical numerical charts retain original source dates, values, populations and intervals. Public export excludes personal context. Release validators and native deployment status verify this background publication; no browser QA is claimed. Publication receipt is written privately after success.